Another case in Kerala: Vaccinated child battles for life after turning rabies positive
Thiruvananthapuram: Five days after a six-year-old girl who received all the anti-rabies treatment passed away, on Saturday, a seven-year-old girl is battling for life after receiving all the anti-rabies treatment.
The anxious mother, hailing from Kollam, of the seven-year-old girl said that a stray dog attacked her daughter on April 8.
'We immediately took her to the hospital and both anti-rabies serum (ARS) and intradermal rabies vaccine (IDRV) was administered,' said the distraught mother.
'There was only one more dose left to be taken, as she got a fever at that time. We then took her to the Taluk hospital and from there to the SAT hospital in the state capital city, where she is now admitted and is serious, according to the doctors. We do not know why this happened as we had adhered to all that the doctors advised us,' said the mother.
Incidentally, this new case comes five days after a six-year-old girl in Malappuram district died of rabies on April 28.
This child was bitten by a stray dog on March 29, and the same day, the same dog had bitten seven other people.
While all except the six-year-old recovered, her condition failed to improve despite taking both the ARS and IDRV, and after battling for her life, she passed away on April 28, leaving many in a state of despair.
Meanwhile, according to statistics from the Kerala Health Directorate, during the period of five years from 2021, there were 102 rabies deaths, of which 19 per cent of the deceased had taken both the vaccines.
Irked by the public outcry against the increased stray dog bites across the state and the deaths taking place even after following all the vaccination protocols, the Kerala government in 2022 constituted a committee to study, and it found that the wounds (bites) of these deaths were in areas of neck, face and head.
This committee, after conducting tests on the ADR and IDRV vaccines, found that it adhered to all the accepted standards.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
12 hours ago
- Time of India
'I don't want to live anymore': Pune techie dies by suicide from 21st floor, leaves heartbreaking note
Pune techie dies by suicide from 21st floor, leaves heartbreaking note In a deeply distressing incident that has sent shockwaves through Pune's bustling IT hub of Hinjawadi, a 25-year-old software professional named Abhilasha Bhausaheb Kothimbhire died by suicide after jumping from the 21st floor of a high-rise residential building. The event took place on May 31, 2025, and an Accidental Death Report (ADR) was registered on June 4, according to officials from the Pimpri Chinchwad Police Station. The tragedy is not only a personal loss to her loved ones but also raises urgent questions about the mental health challenges faced by young professionals in India's tech industry. Abhilasha left behind a heartbreaking suicide note, stating, 'I'm done living. I don't want to live anymore,' and apologized to her parents and friends for the decision she had made. Her story is a grim reminder that behind the gleaming campuses and lucrative salaries of India's booming IT sector, thousands of young employees silently battle immense psychological stress, burnout, and isolation. Tragedy in Pune: Techie ends life with chilling note According to police reports and preliminary investigations, on May 31, at around 4:30 a.m., Abhilasha Kothimbhire arrived at the Crown Green Society in Pune's Hinjawadi area. She proceeded to visit a friend who lived on the 21st floor of the building and jumper from there. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Eat 1 Teaspoon Every Night, See What Happens A Week Later [Video] getfittoday Undo A suicide note was recovered by the police, wherein she expressed her emotional exhaustion and apologized to those close to her. An Accidental Death Report (ADR) was filed by Pimpri Chinchwad police on June 5, officially documenting the circumstances surrounding her death. Social media reaction: A wave of grief and concern Abhilasha's death sparked a wave of reaction on X (formerly Twitter), with the hashtag #RIPAbhilasha and #MentalHealthMatters trending in Pune and Mumbai. Several users posted about the need for redefining hustle culture, sharing their own experiences with burnout and suicidal thoughts. 'A 25-year-old with a future ahead ended it all because she couldn't take it anymore. Shame on our toxic work culture,' wrote one user. 'RIP Abhilasha. We need to start talking more openly about mental health in tech ,' posted another. Also read | Elon Musk swears by this '5-minute rule' and it could guarantee your success too
Time of India
30-05-2025
- Time of India
NMC picks holes in MMCH's report, cites several deficiencies
1 2 3 Daltonganj: The National Medical Commission's (NMC) undergraduate medical education board (UGMEB) has red-flagged nine deficiencies in the Medinirai Medical College Hospital (MMCH) in Daltonganj based on the health institute's annual disclosure report (ADR) in April this year. Medical colleges are mandated to submit their ADR for permission to admit students in the first year of the MBBS courses every calendar year. However, the red flagging has now put the fate of MMCH in a limbo. Principal of MMCH Daltonganj, Dr P N Mahto, said, "The director of UGMEB has issued a show cause notice to this medical college, seeking our response to the issues raised by them." Sources said the UGMEB director, Sukh Lal Meena, sent the notice to this medical college in the first week of May. The deficiencies are varied and broad ranging from faculty crunch to facilities. "This medical college is operating with only 30% of the required faculty and rest are vacant," the principal said. UGMEB also raised concern over the number of beds. It must be 500 as per NMC's norms. MMCH currently has 353 beds. "By the end of Dec, the college will have 500 beds for which works are underway," said the principal. The poor bed occupancy too was highlighted. The normal percentage of bed occupancy is over 90%. However, the UGMEB found it to be only 66.6%. "Once we become a 500-bed hospital, our bed occupancy percentage will increase," the principal added. MMCH also has lesser number of cadavers as opposed to the prescribe 10 in number. "
Time of India
12-05-2025
- Time of India
Avammune Therapeutics raises $12 million to advance cancer therapies
Avammune Therapeutics founders Arun Papaiah, Srinivasan Namala, and Aditya Kulkarni BENGALURU: Biopharmaceutical startup Avammune Therapeutics has raised $12 million (Rs 100 crore) in a Series A funding round co-led by Capital 2B, Shastra VC, and Kotak Lifesciences Fund I, with additional participation from IvyCap Ventures and returning investor 1Crowd. Founded in 2020, Avammune is developing small molecule immunotherapies that activate the body's innate immune system to treat cancer and autoimmune disorders. The latest infusion will fund clinical development of its lead asset AVA-NP-695 – an ENPP1 inhibitor – alongside preclinical work on pipeline candidates, as per a company statement. The company operates out of Philadelphia and Bengaluru and was started by serial biotech entrepreneurs Arun Papaiah, Srinivasan Namala, and Aditya Kulkarni. AVA-NP-695 has demonstrated strong antitumor responses in preclinical models for cancers including osteosarcoma, Ewing's sarcoma, and triple negative breast cancer. It has also been tested in veterinary patients through compassionate-use programs, according to the company. 'Current immuno-oncology drugs mostly target the adaptive immune system and are largely biologics that require injections,' said CEO Papaiah. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like AI guru Andrew Ng recommends: Read These 5 Books And Turn Your Life Around in 2025 Blinkist: Andrew Ng's Reading List Undo 'We're taking a small molecule approach to activating the innate immune system, which could be easier to administer and potentially more accessible, especially in emerging markets.' Unlike traditional therapies such as chemotherapy and radiation, immuno-oncology (IO) treatments aim to harness the immune system to selectively attack cancer cells. While approved IO drugs like checkpoint inhibitors have shown results, only 30-40% of patients respond to them. Targeting innate immunity represents a newer frontier in IO drug development, the company said. The global IO market, currently estimated at $100 billion, is projected to grow at a CAGR of 17%, driven by increasing cancer incidence and demand for novel therapies. Most existing IO therapies are high-cost biologics with limited accessibility in countries like India. 'The best-in-class profile of AVA-NP-695 and its early data in hard-to-treat cancers make it a compelling candidate,' said Shastra VC partner Avijeet Alagathi, noting the lack of progress in osteosarcoma treatment over the past four decades. Avammune's broader pipeline includes AVA-ADR, an ADAR1 p150 inhibitor that has shown in vivo efficacy – an uncommon feat in its category. The company has also developed a proprietary chemical library to target DNA/RNA-binding proteins, which it says allows it to create highly targeted therapies at lower doses. With a team of over 40 across its global operations, Avammune partners with institutions including UCSF, Oxford University, and University of Queensland for early-stage research collaborations. The company plans to initiate human trials for AVA-NP-695 in the near future. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
